Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

FDMT. – 4D Molecular Therapeutics Inc

4D Molecular Therapeutics, Inc.
FDMT
$4.18
Name : 4D Molecular Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $193,636,816.00
EPSttm : -3.18
finviz dynamic chart for FDMT
4D Molecular Therapeutics, Inc.
$4.18
6.91%
$0.27

Float Short %

11.24

Margin Of Safety %

Put/Call OI Ratio

0.17

EPS Next Q Diff

-0.08

EPS Last/This Y

-0.58

EPS This/Next Y

-0.35

Price

3.91

Target Price

29.56

Analyst Recom

1.82

Performance Q

-5.56

Relative Volume

0.29

Beta

2.83

Ticker: FDMT




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07FDMT3.120.220.003937
2025-05-08FDMT3.230.220.003937
2025-05-09FDMT3.090.220.003967
2025-05-12FDMT3.310.220.003959
2025-05-13FDMT3.260.220.003988
2025-05-14FDMT3.140.222.314008
2025-05-15FDMT3.190.222.314008
2025-05-16FDMT3.450.230.004074
2025-05-19FDMT3.780.130.163749
2025-05-20FDMT3.840.130.003838
2025-05-21FDMT3.550.1350.003909
2025-05-22FDMT3.610.1350.003909
2025-05-23FDMT3.50.180.004113
2025-05-27FDMT3.420.181.704125
2025-05-28FDMT3.490.180.004141
2025-05-29FDMT3.710.180.004151
2025-05-30FDMT3.620.180.004151
2025-06-02FDMT3.740.170.004211
2025-06-03FDMT3.870.170.004211
2025-06-04FDMT3.830.170.004239
2025-06-05FDMT3.90.170.004268
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07FDMT3.12-30.6- -3.57
2025-05-08FDMT3.24-30.6- -3.57
2025-05-09FDMT3.08-30.6- -3.57
2025-05-12FDMT3.32-30.6- -3.57
2025-05-13FDMT3.27-30.6- -3.57
2025-05-14FDMT3.13-30.6- -3.57
2025-05-15FDMT3.20-30.6- -3.57
2025-05-16FDMT3.45-30.6- -3.56
2025-05-19FDMT3.80-10.0- -3.56
2025-05-20FDMT3.85-10.0- -3.56
2025-05-21FDMT3.54-10.0- -3.56
2025-05-22FDMT3.61-10.0- -3.56
2025-05-23FDMT3.49-10.0- -3.56
2025-05-27FDMT3.42-10.0- -3.56
2025-05-28FDMT3.48-10.0- -3.56
2025-05-29FDMT3.71-10.0- -3.56
2025-05-30FDMT3.62-10.0- -3.56
2025-06-02FDMT3.73-10.0- -3.56
2025-06-03FDMT3.87-10.0- -3.56
2025-06-04FDMT3.84-10.0- -3.56
2025-06-05FDMT3.91-10.0- -3.56
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07FDMT0.00-25.6713.12
2025-05-08FDMT0.00-25.6713.12
2025-05-09FDMT0.00-25.6713.12
2025-05-12FDMT0.00-24.3012.69
2025-05-13FDMT0.00-24.3012.69
2025-05-14FDMT0.00-24.3012.69
2025-05-15FDMT0.00-24.3012.74
2025-05-16FDMT0.00-24.3012.74
2025-05-19FDMT0.00-23.1212.13
2025-05-20FDMT0.00-23.1212.13
2025-05-21FDMT0.00-23.1212.13
2025-05-22FDMT0.00-23.1212.13
2025-05-23FDMT0.00-23.1212.13
2025-05-27FDMT0.00-9.8412.13
2025-05-28FDMT0.00-9.8411.24
2025-05-29FDMT0.00-9.8411.24
2025-05-30FDMT0.00-9.8411.24
2025-06-02FDMT0.00-8.5811.24
2025-06-03FDMT0.00-8.5811.24
2025-06-04FDMT0.00-8.5811.24
2025-06-05FDMT0.00-8.5811.24
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.86

Avg. EPS Est. Current Quarter

-0.69

Avg. EPS Est. Next Quarter

-0.94

Insider Transactions

Institutional Transactions

-8.58

Beta

2.83

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

20

Growth Score

31

Sentiment Score

38

Actual DrawDown %

92.9

Max Drawdown 5-Year %

Target Price

29.56

P/E

Forward P/E

PEG

P/S

9056.3

P/B

0.39

P/Free Cash Flow

EPS

-3.37

Average EPS Est. Cur. Y​

-3.56

EPS Next Y. (Est.)

-3.91

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

-767126.09

Relative Volume

0.29

Return on Equity vs Sector %

-61.6

Return on Equity vs Industry %

-43.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

4D Molecular Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 227
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.
stock quote shares FDMT. – 4D Molecular Therapeutics Inc Stock Price stock today
news today FDMT. – 4D Molecular Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FDMT. – 4D Molecular Therapeutics Inc yahoo finance google finance
stock history FDMT. – 4D Molecular Therapeutics Inc invest stock market
stock prices FDMT premarket after hours
ticker FDMT fair value insiders trading